Cobalamin Rechecks: Tell the Vet When the Last Supplement Was Given
Cobalamin (B12) recheck results depend on supplement timing. Compare published schedules and learn what dog and cat owners should record before the blood draw.
What the blood test can and cannot show
Cobalamin supports cellular metabolism. Its absorption depends on the small intestine and pancreatic function, so low concentrations can accompany chronic intestinal disease or exocrine pancreatic insufficiency (EPI). Merck reports deficiency in more than 80% of dogs and almost all cats with EPI. It also describes an association between deficiency and poorer outcome in one canine EPI study. This makes monitoring relevant, but a cobalamin result is not a diagnosis of EPI. Merck Veterinary Manual.
A baseline sample taken before supplementation and a recheck taken during treatment answer different questions. Put both reports beside the treatment history before comparing them. The useful question is whether the result fits the patient, the timing, and the veterinarian’s monitoring goal. “Higher than last time” is an incomplete interpretation if the first sample preceded treatment and the second followed a recent dose.
Serum testing measures the concentration in blood, not the amount inside every tissue or the extent of intestinal healing. An improved value can support a treatment assessment without proving that the pet can remain well after supplementation ends. Likewise, ongoing digestive signs require attention even when the laboratory has removed its low flag.
For background on the underlying workup, see the guides to EPI in dogs and canine chronic intestinal disease. Here, the decision is narrower: which supplementation history needs to accompany the recheck result?
Published recheck schedules use different clocks
Texas A&M’s cyanocobalamin protocol describes daily oral supplementation for 8–12 weeks, followed by a serum recheck four weeks after stopping. Its injection protocol describes six weekly subcutaneous injections, another dose a month later, and retesting one month after the last injection. These are laboratory recommendations for the treating veterinarian, rather than a schedule to start independently. Texas A&M cobalamin information.
A clinical review in Today’s Veterinary Practice gives a different oral interval: one week after completing 12 weeks of oral treatment. It gives the same one-month interval after the seventh injection. The 2022 dog and 2024 cat trials also sampled one week after completion, including the injectable groups. A trial visit schedule and a laboratory’s clinical recommendation should therefore be identified separately. Today’s Veterinary Practice review.
The table keeps the end of treatment and the blood draw as separate events. It describes published schedules, not an instruction to interrupt treatment. Ask the clinic which schedule it is using and have the actual appointment date written into the plan.
| Schedule or sampling point | Published timing | What to clarify with the clinic |
|---|---|---|
| Texas A&M oral cyanocobalamin protocol | 8–12 weeks of daily treatment; recheck four weeks after the last dose | Confirm the prescribed course and the planned last-dose date. |
| Texas A&M injection protocol | Six weekly injections, one more a month later; recheck one month after that last injection | Count from the actual last injection, not the date the course began. |
| 2022 dog trial and 2024 cat trial | Final sample one week after completion: week 13 for oral groups, week 11 for injection groups | Do not assume these study visits are the clinic’s chosen recheck schedule. |
| A sample obtained during ongoing treatment | Its meaning depends on the current prescription and recent doses | Tell the team that treatment is continuing and give the latest administration details. |
Sources for the study schedules: 2022 canine trial and 2024 feline trial. Neither trial directly compared a one-week recheck with a four-week recheck to establish which produces better clinical outcomes.
If an appointment moves, report the change before adjusting any treatment. A booking change does not automatically change the last-dose date. Similarly, an unexpected blood test for another problem may occur at a different point in the course. The team can record that context and decide whether that sample answers the intended B12 question.
Why a high value during treatment needs context
In a retrospective study of 25 cats, serum cobalamin was rechecked 27–94 days into an ongoing daily oral course. The authors reported concentrations above the reference interval in all cats, with a median of 2,701 pmol/L. Their study interval was 214–738 pmol/L; some high results could not be quantified fully. Owners were instructed to omit the tablet on the sampling day as part of that study’s protocol. 2017 feline study.
That study-specific preparation is not a reason to skip a prescribed tablet before your own pet’s appointment. More fundamentally, a result measured during a course cannot establish how long the improvement will persist after the course ends. The study supports an increase in serum concentrations with oral treatment; it does not prove that the measured vitamin came only from the previous day’s tablet or that tissue stores remained depleted.
Tell the clinic about B12 from every product you give, including a combined supplement, rather than assuming the separately prescribed tablet is the only relevant item. Bring the packaging or a clear photograph if the formulation is uncertain. The team needs the product information as well as the name “B12.”
Read the result band with the veterinarian
Texas A&M describes supranormal concentrations as expected at its recheck point when stores have been replenished and the underlying disease has resolved. It recommends continued treatment for in-range results, and further investigation with continued supplementation for subnormal results. This is a conditional interpretation: an elevated number alone cannot establish disease remission. Texas A&M interpretation guidance.
| Report finding | Question for the veterinarian | Conclusion the number alone cannot establish |
|---|---|---|
| Above the laboratory’s upper reference limit | Does this fit recent supplementation and the intended sampling point? | That the underlying disease is cured or treatment can stop. |
| Within the reference interval | Is this adequate for this patient’s monitoring goal, or is continued supplementation needed? | That a laboratory “normal” flag ends the treatment plan. |
| Below the reference interval | Should the administration history, ongoing disease, and supplementation plan be reassessed? | That the owner missed doses or a particular route cannot work. |
| Within the interval but below approximately 400 ng/L | How does the lab interval differ from the clinician’s treatment threshold? | That every value below 400 ng/L is below the laboratory’s normal range. |
The approximately 400 ng/L supplementation threshold is distinct from the lower reference limits quoted in Today’s Veterinary Practice: 251 ng/L for dogs and 290 ng/L for cats at the laboratory described. The review also states that dogs and cats with EPI or selective cobalamin deficiency require lifelong supplementation. A reassuring recheck therefore is not a universal stopping rule. Clinical review.
Ask for a clear next step with the result: continue the current prescription, follow a revised prescription, or return for another assessment on a specified date. Avoid translating the table into your own treatment change. The decision also depends on the diagnosis and clinical course, which a single blood concentration cannot supply.
What the dog and cat trials actually found
The 2022 randomized canine study included 46 completing dogs with chronic enteropathy or EPI. At the final recheck, 3 of 14 chronic-enteropathy dogs and 5 of 10 EPI dogs in the injectable groups were below 400 ng/L. In the oral groups, 3 of 13 chronic-enteropathy dogs were below that threshold, while none of the nine EPI dogs were. These are small-group findings at a defined sampling point, not population failure rates. 2022 canine trial.
The authors discussed differences in sampling times, formulations, and owner administration when comparing findings with earlier studies. They did not count remaining chews to verify oral administration. These limitations support reassessment after a course; they do not establish that a low result identifies poor owner adherence or that switching routes is always the answer. Canine study discussion.
The 2024 trial included 48 completing cats. All rose above the lower reference limit of 290 ng/L with oral or subcutaneous treatment. One EPI cat receiving oral treatment had a final value of 352 ng/L: within the study’s reference interval, although below 400 ng/L. Describing that cat as still below the reference interval would confuse two different thresholds. 2024 feline trial.
The feline investigators observed a downward trend between rechecks and noted uncertainty about ideal treatment duration and monitoring after discontinuation. The study was nonblinded; some high values were truncated because too little serum remained for dilution. It did not follow concentrations long enough after treatment ended to establish lasting correction. Feline study limitations.
Both trials came from the Texas A&M GI Lab research group, which also publishes the laboratory protocol. They add prospective evidence, but are not independent replication by unrelated groups. The dog and cat populations were separate studies: their different results do not isolate species as the cause. Both also allowed other medical and dietary treatment, so clinical improvement cannot be assigned to B12 alone.
Bring a dose record the clinic can use
A simple record helps the team reconstruct the timeline. It can be a notebook, phone note, or the clinic’s own form. The format below is a communication aid, not a validated medical tool. Use the prescription and product packaging to fill it in; leave uncertain details marked as uncertain instead of estimating a dose or concentration.
| Record field | What to enter |
|---|---|
| Date and time | Actual administration date and approximate time; label estimates. |
| Product and formulation | Name on the package and the form of B12 if stated; include combination products. |
| Route and amount | By mouth or injection; record the amount actually given and units from the prescription. |
| Who administered it | Owner, family member, or clinic; add the clinic name when records are split. |
| Missed or uncertain administration | A missed dose, an incompletely eaten tablet, vomiting after administration, or uncertainty about who gave it. |
| Sampling details | Blood-draw date and time, testing laboratory, and the clinic’s intended recheck point. |
Keep prescribed and actual administration separate. For example, “prescribed daily; unsure whether Tuesday’s tablet was eaten” is more useful than a row marked “daily” for the whole month. If two people share care, use one record so an empty entry means the same thing to both. Do not add an extra dose to repair a gap without asking the clinic.
At check-in, a useful statement is: “The latest dose was given on [date] at about [time], by [route]. Here is the product and the record of any missed or uncertain doses.” If the pet receives injections at more than one clinic, request the administration dates from each. A scheduled visit is not proof that an injection was given on that date.
Also bring the previous full laboratory report rather than only its highlighted number. Keep the collection date, units, reference interval, and any above-range reporting limit visible. A text message saying “B12 was high” loses information that may matter when the team compares visits. Ask for the new report after this draw and keep it with the same record.
Before leaving, confirm who will contact you about results and how you should continue treatment while waiting. If appetite, vomiting, diarrhea, weight, or general condition changes, contact the clinic rather than waiting silently for the planned recheck. The appointment calendar is a monitoring plan, not a reason to delay discussing a deterioration.
Confirm fasting and laboratory preparation in advance
Texas A&M recommends an 8–12-hour fasted serum sample; its FAQ specifies six hours for diabetic patients. These are laboratory instructions for the veterinary team to adapt. Ask the clinic about food, water, insulin, other medication, and supplements for your particular pet. Do not apply a fasting rule from this page independently to a diabetic or otherwise vulnerable animal. GI Lab FAQ.
For the cobalamin/folate assay, the laboratory lists a minimum of 400 µL of serum for dogs and cats. It requires serum separated from the clot into another tube and recommends overnight shipment frozen or with ice packs. Panels that include additional tests can require different volumes. Handling, storage, packaging, and shipping belong to the submitting team; other laboratories may use different requirements. GI Lab sample requirements.
The GI Lab requires submission through a veterinarian and offers ACVIM-certified internal medicine specialist consultation to submitting veterinarians. Owners receive interpretation and a patient-specific plan through their clinic. This is that laboratory’s stated workflow, rather than a claim about the law or operating rules of every veterinary laboratory. GI Lab services.
A B12 recheck is also distinct from the routine chemistry panel. Confirm what the veterinarian has ordered and which results will be reviewed together. There is no need for the owner to manage a serum tube or arrange independent shipping to make the recheck useful.
When the number leaves questions unanswered
Serum cobalamin and methylmalonic acid (MMA) provide different information. MMA can add evidence about cellular deficiency when serum cobalamin seems reassuring. The canine trial measured both, and they did not change identically in every group. A veterinarian can decide whether further testing would answer a remaining clinical question; a normal B12 concentration alone does not settle every concern. Canine trial measurements.
Compare results using the units and reference interval printed on each report. The 2017 cat study reported pmol/L, whereas the later trials reported ng/L. A value copied from one paper cannot be read against an interval taken from another. If the laboratory or method changes, identify that change in the record and ask how it affects interpretation of the trend.
There is also an important distinction between a high result during prescribed supplementation and an unexplained high result. The clinical review discusses associations with other disease in cats; such a finding deserves clinical context, not a diagnosis based on the number. It does not establish the same risks in dogs by extrapolation, or show that prescribed supplementation caused a disease. Review of high cobalamin results.
For a cat already being investigated for intestinal lymphoma, the recheck belongs alongside the diagnostic record and response to treatment. It cannot replace that workup. For either species, the useful outcome of the visit is a documented interpretation and follow-up plan that connects the blood result to the prescription and the pet’s condition.
Sources
Texas A&M GI Lab: Cobalamin Information — supplementation and recheck recommendations.
Texas A&M GI Lab: Frequently Asked Questions — supplementation effects and preparation.
Texas A&M GI Lab: Sample Requirements — serum volumes and shipping.
Texas A&M Gastrointestinal Laboratory — submission and consultation services.
Schmid and Tolbert: Cobalamin in Health and Disease, Today’s Veterinary Practice — clinical review.
Chang and colleagues, 2022: Oral or injectable cobalamin in dogs — randomized clinical study.
Chang and colleagues, 2024: Oral or subcutaneous cyanocobalamin in cats — randomized clinical study.
Toresson and colleagues, 2017: Oral cobalamin supplementation in cats — retrospective study.
Merck Veterinary Manual: Exocrine Pancreatic Insufficiency in Dogs and Cats — disease context.
